Patents Assigned to Acturum Life Science AB
  • Triazole compounds and their use as gamma secretase modulators
    Patent number: 9718805
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: August 1, 2017
    Assignee: Acturum Life Science AB
    Inventors: Yevgeni Besidski, Ulrika Yngve, Kim Paulsen, Christian Erik Linde, Jonas Malmborg
  • Triazole compounds and their use as gamma secretase modulators
    Patent number: 9611254
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: April 4, 2017
    Assignee: Acturum Life Science AB
    Inventors: Yevgeni Besidski, Ulrika Yngve, Kim Paulsen, Christian Erik Linde, Gunnar Nordvall, Istvan Macsari, Jonas Malmborg
  • Pyrimidine compounds and their use as gamma secretase modulators
    Patent number: 9439904
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: September 13, 2016
    Assignee: Acturum Life Science AB
    Inventors: Yevgeni Besidski, Ulrika Yngve, Kim Paulsen, Christian Erik Linde, Istvan Macsari, Jonas Malmborg, Alexander Paptchikhine, Per Arvidsson
  • 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors
    Patent number: 9440992
    Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: September 13, 2016
    Assignee: Acturum Life Science AB
    Inventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
  • PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS
    Publication number: 20160129002
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Application
    Filed: June 3, 2014
    Publication date: May 12, 2016
    Applicant: Acturum Life Science AB
    Inventors: Yevgeni BESIDSKI, Ulrika YNGVE, Kim PAULSEN, Christian Erik LINDE, Istvan MACSARI, Jonas MALMBORG, Alexander PAPTCHIKHINE, Per ARVIDSSON
  • 2-carboxamide-7-piperazinyl-benzofuran derivatives
    Patent number: 8859534
    Abstract: The present invention relates to compounds of formula (I), wherein R1 is heteroaryl or heterocyclyl, optionally substituted; R2 is C1-4alkyl, heterocyclyl, C1-4alkylaryl, C1-4alkylheteroaryl, carbocyclyl, C1-4alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R3 is hydrogen or C1-4alkyl, or R2 and R3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: October 14, 2014
    Assignee: Acturum Life Science AB
    Inventors: Johan Andersson, Helena Gyback, Anh Johansson, Christian Erik Linde, Jonas Malmstrom, Gunnar Nordvall, Tatjana Weigelt, Gitte Terp
  • TRPA1 receptor antagonist
    Patent number: 8859556
    Abstract: A compound of Formula (I), pharmaceutically acceptable salts thereof, enantiomers, or mixtures thereof; pharmaceutical compositions containing said compounds, enantiomers or mixtures; processes for making said compounds, enantiomers or mixtures; the use of said compounds, enantiomers or mixtures; and medicaments containing the same for treatment of pain and other conditions; and methods of treating pain and other conditions with the same.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: October 14, 2014
    Assignee: Acturum Life Science AB
    Inventors: Mats Svensson, Dirk Weigelt